RxDoctor Payments Data

Michael Attilio, MD

Family Medicine · Barneveld, NYNPI 1215913371

Payments from drug & device makers

$1,260in general payments, 2019–2025

Across 71 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$214
  • GSK$196
  • Novo Nordisk$143
  • Biohaven Pharmaceutical Holding Company Ltd.$89
  • Baxter Healthcare$66
  • Abbott$64
  • plus $488 from 17 others

What the payments were for

  • Food & beverage$1,260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,260 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$30,064
Medicare patients
153
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$96,263
TrulicityDulaglutide51$78,269
EliquisApixaban76$75,294
MounjaroTirzepatide54$61,446
JardianceEmpagliflozin26$44,837
XareltoRivaroxaban37$42,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$39,461
JanuviaSitagliptin Phosphate26$28,965
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$17,341
EntrestoSacubitril/Valsartan12$16,786
Breo ElliptaFluticasone/Vilanterol30$13,162
FarxigaDapagliflozin Propanediol11$11,381
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,297
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$8,897
Albuterol Sulfate HfaAlbuterol Sulfate157$4,697

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$15$139,716105 claims
Novo NordiskOzempic$143$96,26373 claims
PfizerEliquis$214$75,29476 claims
GSKTrelegy Ellipta, Breo Ellipta$196$52,62274 claims
Boehringer IngelheimJardiance$32$44,83726 claims
Johnson & JohnsonXarelto$18$42,02337 claims
MerckJanuvia$17$28,96526 claims
AstraZenecaFarxiga, Breztri Aerosphere$37$20,67826 claims
NovartisEntresto$52$16,78612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Barneveld

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →